A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

Yoshifumi Takei, Kenji Kadomatsu, Yukio Yuzawa, Seiichi Matsuo, Takashi Muramatsu

Research output: Contribution to journalArticle

344 Citations (Scopus)


Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.

Original languageEnglish
Pages (from-to)3365-3370
Number of pages6
JournalCancer Research
Issue number10
Publication statusPublished - 15-05-2004


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this